<DOC>
	<DOCNO>NCT02277574</DOCNO>
	<brief_summary>This Phase 1b , randomize , multi-dose , placebo-controlled , dose-escalation , multi-center study AMP-110 adult subject rheumatoid arthritis .</brief_summary>
	<brief_title>Assess Safety , Tolerability , Pharmacokinetics Clinical Activity AMP-110 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Must able provide write informed consent Body mass index 18.5 35.0 kg/m2 Diagnosis Rheumatoid Arthritis accord 1987 revised American College Rheumatology ( ACR ) criteria Global Functional Class I , II , III accord ACR 1991 revise criterion Must least 4 tender joint 4 swollen joint ( 28joint assesssment ) Use &gt; /= 1 nonsteroidal antiinflammatory drug allow , subject must stable dose &gt; /= 2 week prior randomization Use &gt; /= 1 Disease Modifying Antirheumatic Drugs ( DMARD ) &gt; /= 3 month stable dose &gt; /= 6 week prior randomization Stable use low dose oral corticosteroid ( &lt; /= 10 mg prednisone per day equivalent ) allow ; subject must stable dose &gt; /= 4 week prior randomization Prior Day 0 , use : 1 . Rituximab within 6 month 2 . Abatacept within 3 month 3 . Infliximab , Adalimumab , Certolizumab , Tocilizumab , Cyclosporine , Azathioprine Mycophenolate mofetil within 2 month 4 . Etanercept , Anakinra , immunoglobulin blood product within 28 day 5 . Prior immunotherapy , include high dose oral corticosteroid systemic corticosteroid prednisone , biologics , Janus kinase ( JAK ) inhibitor , tofacitinib investigational therapy must complete least 5 halflives 30 day , whichever longer 6 . Prior exposure T cell deplete agent Campath ( alemtuzumab ) Evidence active recent infection History systemic autoimmune disease Rheumatoid Arthritis ; secondary Sjogren 's syndrome , rheumatoid vasculitis orther extraarticular manifestation RA allow History allergic reaction History anaphylaxis allergic diathesis Clinically significant cardiac disease , include : unstable angina ; myocardial infarction within 6 month ; congestive heart failure ; arrhythmia require active therapy , exception clinically insignificant extrasystole , minor conduction abnormality ; history clinically significant abnormality electrocardiogram Evidence active latent tuberculosis Vaccination live attenuate virus within 2 week prior Day 0 Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Joint disease</keyword>
	<keyword>Musculoskeletal disease</keyword>
</DOC>